The European Commission approved Novo Nordisk’s once-daily Wegovy pill on July 15, 2026, for weight management in adults with obesity and in overweight adults with at least one weight-related health condition. It is the first oral GLP-1 weight-loss treatment authorized across the European Union.
The approval covers oral semaglutide at a dose of 25 milligrams for adults with a body mass index of at least 30, or at least 27 when accompanied by a weight-related condition. The medicine is intended to be used together with diet and physical activity.
Clinical data showed that patients taking the pill lost approximately 17% of their body weight on average, compared with about 3% for those receiving placebo. Discontinuations associated with side effects occurred in 6.9% of patients taking oral Wegovy and 5.9% of the placebo group. The adverse-event profile was consistent with the known gastrointestinal effects of semaglutide.
The decision is more significant than the addition of another Wegovy formulation: it marks the point at which obesity treatment becomes a genuine competition between injections and tablets.
Weekly injections have not prevented GLP-1 medicines from becoming blockbuster products. Even so, some patients dislike needles or find long-term injectable treatment difficult to accept. A daily pill may feel more familiar to people already taking medicines for blood pressure, cholesterol or diabetes.
The tablet will not necessarily replace injections. Weekly dosing can be easier for some patients than remembering a pill every day, and individual preferences will depend on efficacy, tolerability, lifestyle and reimbursement.
Oral Wegovy’s largest contribution may be to expand the number and type of patients willing to begin medical obesity treatment.
Novo Nordisk already sells the pill in the United States, Britain and the United Arab Emirates and plans additional launches during the second half of 2026. EU authorization gives the company an important lead over Eli Lilly’s Foundayo, which has not yet completed the European regulatory process.
That lead can matter in a fast-growing market. Early entry allows a manufacturer to build physician familiarity, reimbursement relationships and patient awareness before competing products arrive.
Oral treatment may also change the industry’s manufacturing challenge. Injectable GLP-1 medicines require sterile filling capacity, injection pens and specialized device supply chains. Tablets can use more established manufacturing and packaging systems, although the higher amount of semaglutide required for oral dosing may increase demand for active pharmaceutical ingredient.
The pill therefore does not eliminate the production problem; it changes where the bottleneck may occur.
Pricing and reimbursement remain decisive. EU-wide marketing authorization does not guarantee uniform coverage because individual European countries make their own reimbursement and pricing decisions. A pill may be more acceptable to patients, but adoption will still be limited when treatment is unavailable through public or private insurance.
Competition is also becoming broader than Novo Nordisk versus Eli Lilly. Pfizer, AstraZeneca, Roche and several Chinese drugmakers are developing oral obesity therapies. Future products will be compared on weight loss, preservation of muscle, gastrointestinal tolerability, dosing restrictions and manufacturing cost.
The market is moving from a race to develop any effective GLP-1 drug toward a portfolio battle over which company can offer the best combination of formulations, prices and clinical profiles for different patients.
